实验概要
Intended Use
Dynabeads® Streptavidin are ideal for numerous applications, including purification of proteins, nucleic acids purification, protein interaction studies, immunoprecipitation, immunoassays, phage display, biopanning, drug screening and cell isolation.
Guidelines for Use
All Dynabeads® Streptavidin can be used with biotinylated molecules. Some beads are more suitable for particular applications due to their characteristics. Dynabeads® M-280 Streptavidin and Dynabeads® MyOne™ Streptavidin T1 are commonly used for protein and nucleic acids applications. Dynabeads® M-270 Streptavidin and Dynabeads® MyOne Streptavidin C1 are preferred for nucleic acid diagnostics, specifically with samples with a high chaotropic salt concentration, immunoassays involving small biotinylated antigens and applications that are not compatible with BSA (these beads are not blocked with BSA). MyOne Dynabeads® offer increased binding capacity and slower sedimentation rate, making them ideal for automated applications and for when larger amounts of biotinylated ligand, or their specific target, need to be isolated.
Description of Materials
Dynabeads® Streptavidin are uniform, superparamagnetic beads with a streptavidin monolayer covalently coupled to the surface. This layer ensures negligible streptavidin leakage while the lack of excess adsorbed streptavidin ensures batch consistency and reproducibility of results. These beads give simple and stable binding of biotinylated molecules such as small molecules, peptides, proteins, antibodies, sugars, lectins, oligonucleotides, DNA/RNA etc.
主要试剂
Dynabeads® Streptavidin Trial Kit
Magnet (Dynal® MPC™) for manual or automated protocols
Mixing device with tilting and rotation
Biotinylated compounds
实验步骤
1. Immobilization Procedure
1) Resuspend the beads in the original vial by rotation or vortexing.
2) Calculate the amount of beads required based on their binding capacity and transfer the beads to a new tube.
3) Wash Dynabeads® to remove preservatives.
4) Place the tube containing the beads on a magnet for 1-2 mins.
5) Remove the supernatant by aspiration with a pipette while the tube is on the magnet.
6) Remove the tube from the magnet.
7) Add washing buffer along the inside of the tube where the beads are collected and resuspend (same volume of washing buffer as the initial volume of Dynabeads® taken from the vial or larger).
8) Repeat steps 4 to 7 twice, for a total of 3 washes.
2. General Immobilization Protocol
1) Add the biotinylated molecule to the washed Dynabeads® .
2) Incubate for 15-30 min at room temperature with gentle rotation of the tube.
3) Place the tube in a magnet for 2-3 mins and discard the supernatant.
4) Wash the coated beads 3-4 times in washing buffer.
5) Resuspend to desired concentration in a suitable buffer for your downstream use.
3. Release of Immobilized Biotinylated Molecules
The biotin-streptavidin bond is broken by harsh conditions. 5 mins incubation at 65°C or 2 mins at 90°C in 10 mM EDTA pH 8.2 with 95% formamide will typically dissociate >96% of immobilized biotinylated DNA. Alternatively, boi the sample for 5 mins in 0.1% SDS for dissociation. Please note that proteins will be denatured by such treatmen and Dynabeads® Streptavidin can not be re-used. It has also been reported that the biotin-streptavidin interaction can be broken by a short incubation in nonionic aqueous solution at temperature above 70°C.
注意事项
Critical Notes
1. In the protocols we recommend keeping the tube on the magnet for up to 2 mins to ensure that all the beads are collected on the tube wall. For non-viscous samples, separation is often complete in under 1 min, once you can see the beads collected.
2. If you do not need to remove preservatives or change buffers you can omit Washing Procedure.
3. For diluted sample or large sample volumes, increase the incubation time or isolate in smaller batches using the same beads in each batch.
4. Use a mixer to tilt/rotate the tubes so Dynabeads® do not settle at the tube bottom.
5. Avoid air bubbles during pipetting.
6. Free biotin or biotinylated primer in the sample will reduce the binding capacity of the beads. A disposable separation column or a spin column will remove unincorporated biotin. Run the PCR with limiting concentrations of biotinylated primer, or remove free biotinylated primer by ultrafiltration, microdialysis or other clean-up protocols.
Arrowhead是一家临床阶段的生物技术公司,致力于利用RNA干扰(RNAi)抑制致病基因的转录后表达,开发治疗难治性疾病的创新药物。近日,该公司宣布,评估RNAi药物ARO-AAT的II期研究AR......
Arrowhead是一家临床阶段的生物技术公司,致力于利用RNA干扰(RNAi)抑制致病基因的转录后表达,开发治疗难治性疾病的创新药物。近日,该公司宣布,评估RNAi药物ARO-AAT的II期研究AR......
Alnylam制药公司是RNAi疗法开发领域的领军企业,该公司药物Onpattro(patisiran)于2018年8月获美国和欧盟批准,用于遗传性ATTR(hATTR)淀粉样变性成人患者第1阶段或第......
TheMedicinesCompany(TMC)公司近日在费城举行的2019年美国心脏协会(AHA)年度科学会议上公布了siRNA降脂药物inclisiranIII期临床研究ORION-10的详细数据......
TheMedicinesCompany(TMC)公司近日公布siRNA降脂药物inclisiran两项III期临床研究(ORION-9,ORION-10)的积极顶线数据。ORION-9研究在杂合子家族......
TheMedicinesCompany公司近日在欧洲心脏病学会(ESC)2019年会上公布了siRNA降脂药物inclisiran每6个月给药一次降低LDL-C的首个关键性III期研究ORION-11......
Arrowhead是一家RNAi治疗公司,目前正与强生合作开发有望功能性治愈乙型肝炎病毒(HBV)感染的RNAi药物。近日,该公司宣布,强生旗下杨森制药已开始在IIb期研究(REEF-1)对不同组合方......
TheMedicinesCompany是一家生物制药公司,专注于应对当今最大全球医疗挑战和负担——心血管疾病,其目的是阻止动脉粥样硬化的致命性进展和高水平低密度脂蛋白胆固醇(LDL-C)造成的心血管风......
Alnylam制药公司是RNAi疗法开发领域的领军企业,该公司药物Onpattro(patisiran)于2018年8月获美国和欧盟批准,用于遗传性ATTR(hATTR)淀粉样变性成人患者第1阶段或第......
行业领先的RNAi疗法公司AlnylamPharmaceuticals与RegeneronPharmaceuticals公司联合宣布,双方达成研发协议,合作发现、开发和推广RNAi疗法,治疗多种类型疾......